Free Trial

Cellebrite DI (NASDAQ:CLBT) Given New $26.00 Price Target at Lake Street Capital

Cellebrite DI logo with Business Services background

Cellebrite DI (NASDAQ:CLBT - Free Report) had its target price hoisted by Lake Street Capital from $17.00 to $26.00 in a research report report published on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Other analysts have also issued research reports about the company. Craig Hallum lifted their price target on Cellebrite DI from $23.00 to $24.00 and gave the stock a "buy" rating in a research report on Thursday, November 7th. Needham & Company LLC restated a "buy" rating and issued a $28.00 price objective on shares of Cellebrite DI in a research note on Friday. Finally, JPMorgan Chase & Co. upped their target price on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Cellebrite DI presently has an average rating of "Buy" and a consensus target price of $23.43.

Get Our Latest Research Report on Cellebrite DI

Cellebrite DI Stock Performance

Shares of Cellebrite DI stock traded down $0.21 on Friday, reaching $20.29. The stock had a trading volume of 3,087,426 shares, compared to its average volume of 1,928,881. The business's 50-day moving average price is $22.58 and its two-hundred day moving average price is $19.28. The stock has a market cap of $4.18 billion, a P/E ratio of -13.09, a price-to-earnings-growth ratio of 3.72 and a beta of 1.47. Cellebrite DI has a fifty-two week low of $10.24 and a fifty-two week high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 82.28% and a positive return on equity of 122.59%. As a group, equities analysts forecast that Cellebrite DI will post 0.32 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cellebrite DI

A number of hedge funds have recently made changes to their positions in the business. Pathway Financial Advisers LLC grew its position in Cellebrite DI by 1,583.8% in the third quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company's stock valued at $74,000 after acquiring an additional 4,118 shares during the period. Tower View Wealth Management LLC boosted its stake in shares of Cellebrite DI by 1.2% in the 3rd quarter. Tower View Wealth Management LLC now owns 130,647 shares of the company's stock valued at $2,200,000 after purchasing an additional 1,500 shares in the last quarter. Meitav Investment House Ltd. grew its holdings in shares of Cellebrite DI by 29.7% in the 3rd quarter. Meitav Investment House Ltd. now owns 2,066,322 shares of the company's stock worth $34,797,000 after purchasing an additional 473,293 shares during the last quarter. Pembroke Management LTD increased its position in shares of Cellebrite DI by 24.3% during the 3rd quarter. Pembroke Management LTD now owns 1,908,345 shares of the company's stock worth $32,137,000 after purchasing an additional 372,619 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its holdings in Cellebrite DI by 8.3% during the 3rd quarter. Janney Montgomery Scott LLC now owns 51,155 shares of the company's stock valued at $861,000 after purchasing an additional 3,912 shares during the last quarter. Institutional investors and hedge funds own 45.88% of the company's stock.

About Cellebrite DI

(Get Free Report)

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

Featured Articles

Analyst Recommendations for Cellebrite DI (NASDAQ:CLBT)

Should You Invest $1,000 in Cellebrite DI Right Now?

Before you consider Cellebrite DI, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.

While Cellebrite DI currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Goldman Sachs' 2025 Market Outlook: Top 3 Stock Picks

Goldman Sachs' 2025 Market Outlook: Top 3 Stock Picks

As Wall Street's 2025 predictions roll in, Goldman Sachs is focusing on manufacturing, energy, and domestic producers as key sectors for growth.

Recent Videos

NVIDIA Earnings: Will it Spark a Rally or Trigger a Sell-Off?
Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
The EXACT Date of Next Stock Market Crash

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines